<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:58:23 -0700</creation_date>
  <update_date>2013-01-15 18:58:23 -0700</update_date>
  <accession>HMDBP01652</accession>
  <secondary_accessions>
    <accession>6982</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
  </synonyms>
  <gene_name>ADORA2A</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01847</accession>
      <name>Caffeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00050</accession>
      <name>Adenosine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01889</accession>
      <name>Theophylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14502</accession>
      <name>Mefloquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14789</accession>
      <name>Dyphylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14944</accession>
      <name>Pentoxifylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15415</accession>
      <name>Oxtriphylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02825</accession>
      <name>Theobromine</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleotide receptor activity, g-protein coupled</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purinergic nucleotide receptor activity, g-protein coupled</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenosine receptor activity, g-protein coupled</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:2</chromosome_location>
    <locus>22q11.23</locus>
    <gene_sequence>&gt;1239 bp
ATGCCCATCATGGGCTCCTCGGTGTACATCACGGTGGAGCTGGCCATTGCTGTGCTGGCC
ATCCTGGGCAATGTGCTGGTGTGCTGGGCCGTGTGGCTCAACAGCAACCTGCAGAACGTC
ACCAACTACTTTGTGGTGTCACTGGCGGCGGCCGACATCGCAGTGGGTGTGCTCGCCATC
CCCTTTGCCATCACCATCAGCACCGGGTTCTGCGCTGCCTGCCACGGCTGCCTCTTCATT
GCCTGCTTCGTCCTGGTCCTCACGCAGAGCTCCATCTTCAGTCTCCTGGCCATCGCCATT
GACCGCTACATTGCCATCCGCATCCCGCTCCGGTACAATGGCTTGGTGACCGGCACGAGG
GCTAAGGGCATCATTGCCATCTGCTGGGTGCTGTCGTTTGCCATCGGCCTGACTCCCATG
CTAGGTTGGAACAACTGCGGTCAGCCAAAGGAGGGCAAGAACCACTCCCAGGGCTGCGGG
GAGGGCCAAGTGGCCTGTCTCTTTGAGGATGTGGTCCCCATGAACTACATGGTGTACTTC
AACTTCTTTGCCTGTGTGCTGGTGCCCCTGCTGCTCATGCTGGGTGTCTATTTGCGGATC
TTCCTGGCGGCGCGACGACAGCTGAAGCAGATGGAGAGCCAGCCTCTGCCGGGGGAGCGG
GCACGGTCCACACTGCAGAAGGAGGTCCATGCTGCCAAGTCACTGGCCATCATTGTGGGG
CTCTTTGCCCTCTGCTGGCTGCCCCTACACATCATCAACTGCTTCACTTTCTTCTGCCCC
GACTGCAGCCACGCCCCTCTCTGGCTCATGTACCTGGCCATCGTCCTCTCCCACACCAAT
TCGGTTGTGAATCCCTTCATCTACGCCTACCGTATCCGCGAGTTCCGCCAGACCTTCCGC
AAGATCATTCGCAGCCACGTCCTGAGGCAGCAAGAACCTTTCAAGGCAGCTGGCACCAGT
GCCCGGGTCTTGGCAGCTCATGGCAGTGACGGAGAGCAGGTCAGCCTCCGTCTCAACGGC
CACCCGCCAGGAGTGTGGGCCAACGGCAGTGCTCCCCACCCTGAGCGGAGGCCCAATGGC
TATGCCCTGGGGCTGGTGAGTGGAGGGAGTGCCCAAGAGTCCCAGGGGAACACGGGCCTC
CCAGACGTGGAGCTCCTTAGCCATGAGCTCAAGGGAGTGTGCCCAGAGCCCCCTGGCCTA
GATGACCCCCTGGCCCAGGATGGAGCAGGAGTGTCCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>412</residue_number>
    <molecular_weight>44706.9</molecular_weight>
    <theoretical_pi>8.05</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>8-32</region>
      <region>43-66</region>
      <region>78-100</region>
      <region>121-143</region>
      <region>174-198</region>
      <region>235-258</region>
      <region>267-290</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Adenosine receptor A2a
MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAAADIAVGVLAI
PFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAIDRYIAIRIPLRYNGLVTGTR
AKGIIAICWVLSFAIGLTPMLGWNNCGQPKEGKNHSQGCGEGQVACLFEDVVPMNYMVYF
NFFACVLVPLLLMLGVYLRIFLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIIVG
LFALCWLPLHIINCFTFFCPDCSHAPLWLMYLAIVLSHTNSVVNPFIYAYRIREFRQTFR
KIIRSHVLRQQEPFKAAGTSARVLAAHGSDGEQVSLRLNGHPPGVWANGSAPHPERRPNG
YALGLVSGGSAQESQGNTGLPDVELLSHELKGVCPEPPGLDDPLAQDGAGVS</protein_sequence>
  </protein_properties>
  <genbank_protein_id>189066537</genbank_protein_id>
  <uniprot_id>P29274</uniprot_id>
  <uniprot_name>AA2AR_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AK312946</genbank_gene_id>
  <genecard_id>ADORA2A</genecard_id>
  <geneatlas_id>ADORA2A</geneatlas_id>
  <hgnc_id>HGNC:263</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Furlong TJ, Pierce KD, Selbie LA, Shine J: Molecular characterization of a human brain adenosine A2 receptor.  Brain Res Mol Brain Res. 1992 Sep;15(1-2):62-6.</reference_text>
      <pubmed_id>1331670</pubmed_id>
    </reference>
    <reference>
      <reference_text>Le F, Townsend-Nicholson A, Baker E, Sutherland GR, Schofield PR: Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A. Biochem Biophys Res Commun. 1996 Jun 14;223(2):461-7.</reference_text>
      <pubmed_id>8670304</pubmed_id>
    </reference>
    <reference>
      <reference_text>Collins JE, Wright CL, Edwards CA, Davis MP, Grinham JA, Cole CG, Goward ME, Aguado B, Mallya M, Mokrab Y, Huckle EJ, Beare DM, Dunham I: A genome annotation-driven approach to cloning the human ORFeome.  Genome Biol. 2004;5(10):R84. Epub 2004 Sep 30.</reference_text>
      <pubmed_id>15461802</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kim J, Wess J, van Rhee AM, Schoneberg T, Jacobson KA: Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem. 1995 Jun 9;270(23):13987-97.</reference_text>
      <pubmed_id>7775460</pubmed_id>
    </reference>
    <reference>
      <reference_text>Milojevic T, Reiterer V, Stefan E, Korkhov VM, Dorostkar MM, Ducza E, Ogris E, Boehm S, Freissmuth M, Nanoff C: The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor. Mol Pharmacol. 2006 Apr;69(4):1083-94. Epub 2005 Dec 9.</reference_text>
      <pubmed_id>16339847</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC: The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science. 2008 Nov 21;322(5905):1211-7. Epub 2008 Oct 2.</reference_text>
      <pubmed_id>18832607</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.</reference_text>
      <pubmed_id>10391209</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Riksen NP, Franke B, van den Broek P, Smits P, Rongen GA: The 1976C&gt;T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genomics. 2007 Jul;17(7):551-4.</reference_text>
        <pubmed_id>17558310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, Shryock J, Belardinelli L, Hintze TH: Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol. 2007 Jun;49(6):369-75.</reference_text>
        <pubmed_id>17577101</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Cornelis MC, El-Sohemy A, Campos H: Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr. 2007 Jul;86(1):240-4.</reference_text>
        <pubmed_id>17616786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Trincavelli ML, Daniele S, Martini C: Adenosine receptors: what we know and what we are learning.  Curr Top Med Chem. 2010;10(9):860-77.</reference_text>
        <pubmed_id>20370662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Schenone S, Brullo C, Musumeci F, Bruno O, Botta M: A1 receptors ligands: past, present and future trends.  Curr Top Med Chem. 2010;10(9):878-901.</reference_text>
        <pubmed_id>20370661</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Ezeamuzie CI, Khan I: The role of adenosine A(2) receptors in the regulation of TNF-alpha production and PGE(2) release in mouse peritoneal macrophages. Int Immunopharmacol. 2007 Apr;7(4):483-90. Epub 2006 Dec 29.</reference_text>
        <pubmed_id>17321471</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Kreckler LM, Wan TC, Ge ZD, Auchampach JA: Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther. 2006 Apr;317(1):172-80. Epub 2005 Dec 9.</reference_text>
        <pubmed_id>16339914</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Kreckler LM, Gizewski E, Wan TC, Auchampach JA: Adenosine suppresses lipopolysaccharide-induced tumor necrosis factor-alpha production by murine macrophages through a protein kinase A- and exchange protein activated by cAMP-independent signaling pathway. J Pharmacol Exp Ther. 2009 Dec;331(3):1051-61. Epub 2009 Sep 11.</reference_text>
        <pubmed_id>19749080</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, Chapelier A, Bellamy JF, Devillier P: The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol. 2010 Mar;159(6):1304-11. Epub 2010 Feb 5.</reference_text>
        <pubmed_id>20136829</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Funakoshi H, Zacharia LC, Tang Z, Zhang J, Lee LL, Good JC, Herrmann DE, Higuchi Y, Koch WJ, Jackson EK, Chan TO, Feldman AM: A1 adenosine receptor upregulation accompanies decreasing myocardial adenosine levels in mice with left ventricular dysfunction. Circulation. 2007 May 1;115(17):2307-15. Epub 2007 Apr 16.</reference_text>
        <pubmed_id>17438146</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adenosine</name>
        <accession>HMDB00050</accession>
      </metabolite>
      <reference>
        <reference_text>Haschemi A, Wagner O, Marculescu R, Wegiel B, Robson SC, Gagliani N, Gallo D, Chen JF, Bach FH, Otterbein LE: Cross-regulation of carbon monoxide and the adenosine A2a receptor in macrophages. J Immunol. 2007 May 1;178(9):5921-9.</reference_text>
        <pubmed_id>17442976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theophylline</name>
        <accession>HMDB01889</accession>
      </metabolite>
      <reference>
        <reference_text>Pechlivanova DM, Georgiev VP: Effects of single and long-term theophylline treatment on the threshold of mechanical nociception: contribution of adenosine A1 and alpha2-adrenoceptors. Methods Find Exp Clin Pharmacol. 2005 Nov;27(9):659-64.</reference_text>
        <pubmed_id>16357952</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theophylline</name>
        <accession>HMDB01889</accession>
      </metabolite>
      <reference>
        <reference_text>Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists.  Prog Clin Biol Res. 1987;230:41-63.</reference_text>
        <pubmed_id>3588607</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefloquine</name>
        <accession>HMDB14502</accession>
      </metabolite>
      <reference>
        <reference_text>Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward SE, Weiss SM, Williamson DS: Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9. Epub 2008 Mar 30.</reference_text>
        <pubmed_id>18406614</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dyphylline</name>
        <accession>HMDB14789</accession>
      </metabolite>
      <reference>
        <reference_text>Schwabe U, Ukena D, Lohse MJ: Xanthine derivatives as antagonists at A1 and A2 adenosine receptors.  Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):212-21.</reference_text>
        <pubmed_id>2997628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentoxifylline</name>
        <accession>HMDB14944</accession>
      </metabolite>
      <reference>
        <reference_text>Kreth S, Ledderose C, Luchting B, Weis F, Thiel M: Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock. 2010 Jul;34(1):10-6.</reference_text>
        <pubmed_id>19997047</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxtriphylline</name>
        <accession>HMDB15415</accession>
      </metabolite>
      <reference>
        <reference_text>Pechlivanova DM, Georgiev VP: Effects of single and long-term theophylline treatment on the threshold of mechanical nociception: contribution of adenosine A1 and alpha2-adrenoceptors. Methods Find Exp Clin Pharmacol. 2005 Nov;27(9):659-64.</reference_text>
        <pubmed_id>16357952</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxtriphylline</name>
        <accession>HMDB15415</accession>
      </metabolite>
      <reference>
        <reference_text>Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists.  Prog Clin Biol Res. 1987;230:41-63.</reference_text>
        <pubmed_id>3588607</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theobromine</name>
        <accession>HMDB02825</accession>
      </metabolite>
      <reference>
        <reference_text>Chou CC, Vickroy TW: Antagonism of adenosine receptors by caffeine and caffeine metabolites in equine forebrain tissues. Am J Vet Res. 2003 Feb;64(2):216-24.</reference_text>
        <pubmed_id>12602592</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theobromine</name>
        <accession>HMDB02825</accession>
      </metabolite>
      <reference>
        <reference_text>Riksen NP, Franke B, van den Broek P, Smits P, Rongen GA: The 1976C&gt;T polymorphism in the adenosine A2A receptor gene does not affect the vasodilator response to adenosine in humans in vivo. Pharmacogenet Genomics. 2007 Jul;17(7):551-4.</reference_text>
        <pubmed_id>17558310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theobromine</name>
        <accession>HMDB02825</accession>
      </metabolite>
      <reference>
        <reference_text>Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, Shryock J, Belardinelli L, Hintze TH: Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol. 2007 Jun;49(6):369-75.</reference_text>
        <pubmed_id>17577101</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theobromine</name>
        <accession>HMDB02825</accession>
      </metabolite>
      <reference>
        <reference_text>Cornelis MC, El-Sohemy A, Campos H: Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Am J Clin Nutr. 2007 Jul;86(1):240-4.</reference_text>
        <pubmed_id>17616786</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theobromine</name>
        <accession>HMDB02825</accession>
      </metabolite>
      <reference>
        <reference_text>Fisone G, Borgkvist A, Usiello A: Caffeine as a psychomotor stimulant: mechanism of action.  Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.</reference_text>
        <pubmed_id>15095008</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theobromine</name>
        <accession>HMDB02825</accession>
      </metabolite>
      <reference>
        <reference_text>Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists.  Prog Clin Biol Res. 1987;230:41-63.</reference_text>
        <pubmed_id>3588607</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
